Loading
A phase 3 trial of Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide and Tocilizumab in non-Hodgkin lymphoma, run by Hoffmann-La Roche, now recruiting.
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma is a phase 3 interventional study registered as NCT06084936 by Hoffmann-La Roche, with 182 participants planned, started 2023-10-22 and due to reach its primary completion in 2027-08-31. Interventions recorded: Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide and Tocilizumab.
Shares Tocilizumab, Glofitamab, Flatiron Health (Roche), Rituximab and the tag pipeline.
Shares Tocilizumab, Glofitamab, Flatiron Health (Roche), Obinutuzumab and the tag pipeline.
Shares Glofitamab, Flatiron Health (Roche), Obinutuzumab, T-cell engagers (bispecific) and the tag pipeline.
Shares Glofitamab, Obinutuzumab, Mantle cell lymphoma and the tag pipeline.
Shares Glofitamab, Obinutuzumab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Bendamustine, Obinutuzumab, Rituximab and the tag pipeline.
Shares Obinutuzumab, Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Bendamustine, Rituximab and the tag pipeline.